<SEC-DOCUMENT>0001171843-21-004353.txt : 20210615
<SEC-HEADER>0001171843-21-004353.hdr.sgml : 20210615
<ACCEPTANCE-DATETIME>20210615161514
ACCESSION NUMBER:		0001171843-21-004353
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210615
FILED AS OF DATE:		20210615
DATE AS OF CHANGE:		20210615

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		211018730

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_061521.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>UNITED STATES </b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Washington, D.C. 20549 </b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 18pt; text-align: center"><b>FORM 6-K</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>REPORT OF FOREIGN PRIVATE ISSUER </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PURSUANT TO RULE 13a-16 OR 15d-16 </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>Date of report: June 15, 2021 </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>Commission File Number: 001-38844</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="font-size: 24pt; text-align: center; margin: 0pt 0"><b>GENFIT S.A. </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Translation of registrant&rsquo;s name into English) </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Parc Eurasant&eacute;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>885, avenue Eug&egrave;ne Avin&eacute;e</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>59120 Loos, France</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Address of principal executive office)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F:</p>

<p style="font-size: 10pt; margin: 0pt 0">&#9746; Form 20-F &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#9744; Form 40-F</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): &#9744;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): &#9744;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>EXHIBIT LIST</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&nbsp;</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 6%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 4%">&nbsp;</td>
    <td style="width: 90%">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>
    <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: black 1pt solid"><b>Exhibit</b></p></td>
    <td>&nbsp;</td>
    <td>
    <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: black 1pt solid"><b>Description</b></p></td></tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="exh_991.htm"><font style="font-size: 10pt">99.1</font></a></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><a href="exh_991.htm"><font style="font-size: 10pt">Press Release dated June, 15 2021.</font></a></td></tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
  </table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>SIGNATURES </b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 48%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 43%">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="3" style="vertical-align: top"><font style="font-size: 10pt"><b>GENFIT S.A.</b></font></td></tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Date: June 15, 2021</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">By:</font></td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="vertical-align: top; border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Pascal PRIGENT</font></td></tr>
  <tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Name: Pascal PRIGENT</font></td></tr>
  <tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Title: Chief Executive Officer</font></td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="margin-top: 0; margin-bottom: 0; text-align: right"><b>Exhibit 99.1</b></p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"><img src="hdr.jpg" alt=""></p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; text-align: center; text-indent: 0.2pt"><b>GENFIT: June 15, 2021
Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders&rsquo; vote but quorum not met on first
convening</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-indent: 120.75pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><font style="font-family: Symbol">&middot;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Quorum
                                            of 18.19% on first convening</b></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><font style="font-family: Symbol">&middot;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Combined
                                            Shareholders Meeting will be reconvened on June 30, 2021 with the same agenda</b></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><font style="font-family: Symbol">&middot;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Votes
                                            cast on the first convening remain valid for the second convening</b></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><font style="font-family: Symbol">&middot;</font></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Shareholder
                                            engagement remains critical for the approval of the resolutions submitted to the Extraordinary
                                            General Meeting</b></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt"><b>&nbsp;</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify"><b>Lille, France; Cambridge, MA; June 15, 2021</b> - <b>GENFIT
(Nasdaq and Euronext: GNFT)</b>, a late- stage biopharmaceutical company dedicated to improving the lives of patients with metabolic
and liver diseases, today announced that the June 15, 2021 Combined Shareholders Meeting obtained a wide support for the resolutions
submitted to the shareholders vote, however, quorum was not met on first convening. A new Combined Shareholders Meeting to vote on the
same agenda will be convened on June 30, 2021 at 2.30pm Paris time. The agenda and resolutions remain unchanged. The quorum on first
convening amounted to 18.19%. As a reminder, on second convening the required quorum to validly deliberate at the Extraordinary General
Meeting is 20%.</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify"><b>Pascal Prigent, CEO of GENFIT </b>commented: &ldquo;<i>We
thank all the shareholders who have already voted. We are now counting on the support of shareholders who have not voted on first convening
to vote at the next shareholders meeting on June 30, 2021. GENFIT is your company, your vote is vital.</i>&rdquo;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify"><b>Shareholders can still vote by post and send their proxy
forms until June 27, 2021 at midnight (00:00), Paris time and vote electronically via the Votaccess platform starting on June 17, 2021
until June 29, 2021 at 3 p.m., Paris time.</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify"><b>&nbsp;</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">In accordance with decree n&deg;2021-255 of March 09, 2021
extending the application of measures of ordinance n&deg;2020-321 of March 25, 2020 and its application decree n&deg;2020-418 of April
10, 2020 which was extended until July 31, 2021 by decree n&deg; 2021-255 of March 09, 2021, this Combined General Meeting, to be held
upon second convening, will be conducted behind closed doors at the Company&rsquo;s headquarters at Parc Eurasant&eacute;, 885 avenue
Eug&egrave;ne Avin&eacute;e, Loos, 59120 France, meaning without the physical presence of shareholders and others who are usually entitled
to attend.</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 4pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="white-space: nowrap; width: 80%"><p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #706F61"><b>GENFIT</b> | 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</p></td><td style="width: 20%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin-top: 0pt; margin-bottom: 0pt"><img src="hdr.jpg" alt="">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">The convening notice, including the agenda and participation
and voting instructions for the Combined Shareholders Meeting on second convening will be published on June 18, 2021, in the French Legal
Announcements Bulletin (<i>Bulletin des Annonces L&eacute;gales Obligatoires</i>). As shareholders will be unable to participate physically
in the Combined General Meeting, admission cards will therefore not be delivered.</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">In accordance with articles R.225-77 and R.225-79 of the
French Commercial Code, proxy forms sent to the Company, electronic votes and voting powers given to the Combined Shareholders Meeting
on first convening remain valid for the Combined Shareholders Meeting called to vote on the same agenda on second convening on June 30,
2021, as long as the shares voted remain in the respective shareholders&rsquo; accounts.</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">Shareholders that have not cast their votes are invited
to consult the convening notice to be published on June 18, 2021 in the French Legal Announcements Bulletin (<i>Bulletin des Annonces
L&eacute;gales Obligatoires</i>) and to visit our dedicated website (whose address is as follows) for more information on how to participate
in the Combined Shareholders Meeting on second convening on June 30, 2021: <u>https://ir.genfit.com/financial-information/shareholders-meeting</u>.</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify"><b><u>Composition of the Combined General Meeting committee</u></b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><b>&nbsp;</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">The Combined General Meeting will be chaired by Mr. Jean-Fran&ccedil;ois
Mouney, Chairman of the Board of Directors.</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">Given the current pandemic and in accordance with the provisions
of the Decree, the Company informs that it has appointed as observers (<i>scrutateurs</i>) of the Combined General Meeting: Biotech Avenir
and University of Lille, which have each accepted this appointment.</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify"><b><u>Combined Shareholders Meeting broadcast details</u></b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><b>&nbsp;</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">Although quorum was not met on first convening, the Board
of Directors and Management would like to provide a summary business development update. As a result, the Company will audio broadcast
the Combined General Meeting live on the Company&rsquo;s website (https://ir.genfit.com). A replay will be available at the Investors
section of our website (https://ir.genfit.com) under the &ldquo;Events&rdquo; section and on the &ldquo;Shareholders Meeting&rdquo; page
under &ldquo;Financials&rdquo;, as soon as possible at the end of the Combined Shareholders Meeting on first convening and at the latest
before the end of the fifth business day after the second convening of the Combined Shareholders Meeting.</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">The French live broadcast will be accessible by calling
+33 (0) 1 7037 7166 (France) and +44 (0) 33 0551 0200 (UK) five minutes prior to the start time (Password: Genfit).</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="white-space: nowrap; width: 80%"><p style="font-size: 10pt; margin: 0pt 0 0pt 1pt; color: #706F61"><b>GENFIT</b> | 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</p></td><td style="width: 20%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><img src="hdr.jpg" alt="">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify"><b><u>Preparatory documents</u></b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><b>&nbsp;</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">Preparatory documents for the Combined General Meeting according
to article R.22-10-23 of the French Commercial Code were uploaded on the Company&rsquo;s website <u>http://www.genfit.fr</u> on May 25,
2021.</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-weight: bold; text-align: justify">ABOUT GENFIT</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><b>&nbsp;</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">GENFIT is a late-stage biopharmaceutical company dedicated
to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear
receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently
enrolling in ELATIVE&trade;, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). Elafibranor
is an investigational compound that has not been reviewed and has not received approval by any regulatory authority. As part of GENFIT&rsquo;s
comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4&reg;, a new, non-invasive
blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. NIS4&reg; technology has been
licensed to LabCorp&reg; in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test
powered by NIS4&reg; technology. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded
company listed on the Nasdaq Global Select Market and on compartment B of Euronext&rsquo;s regulated market in Paris (Nasdaq and Euronext:
GNFT). <font style="font-size: 10pt"><u>www.genfit.com</u></font></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-weight: bold; text-align: justify">FORWARD LOOKING STATEMENTS</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><b>&nbsp;</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">This press release contains certain forward-looking
statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, including
statements regarding the reconvening of our shareholders meeting and the voting results. The use of certain words, including &ldquo;consider&rdquo;,
&ldquo;contemplate&rdquo;, &ldquo;think&rdquo;, &ldquo;aim&rdquo;, &ldquo;expect&rdquo;, &ldquo;understand&rdquo;, &ldquo;should&rdquo;,
&ldquo;aspire&rdquo;, &ldquo;estimate&rdquo;, &ldquo;believe&rdquo;, &ldquo;wish&rdquo;, &ldquo;may&rdquo;, &ldquo;could&rdquo;, &ldquo;allow&rdquo;,
&ldquo;seek&rdquo;, &ldquo;encourage&rdquo; or &ldquo;have confidence&rdquo; or (as the case may be) the negative forms of such terms
or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although
the Company believes its projections are based on reasonable expectations and assumptions of the Company&rsquo;s management, these forward-looking
statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from
those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things,
the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from,
its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange
rate fluctuations and the Company&rsquo;s continued ability to raise capital to fund its development, as well as those risks and uncertainties
discussed or identified in the Company&rsquo;s public filings with the AMF, including those listed in Chapter 2 &ldquo;Main Risks and
Uncertainties&rdquo; of the Company&rsquo;s 2020 Universal Registration Document filed with the <b>AMF </b>on 23 April 2021 under n&deg;
D.21-0350, which is available on the Company&rsquo;s website (<u>www.genfit.com</u>) and on the website of the <b>AMF </b>(www.amf-france.org)
and public filings and reports filed with the U.S. Securities and Exchange Commission (&ldquo;<b>SEC</b>&rdquo;) including the Company&rsquo;s
2020 Annual Report on Form 20-F filed with the <b>SEC</b> on April 23, 2021. In addition, even if the Company&rsquo;s results, performance,
financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of
the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to
update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-weight: bold; text-align: left"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="white-space: nowrap; width: 80%"><p style="font-size: 10pt; margin: 0pt 0 0pt 1pt; color: #706F61"><b>GENFIT</b> | 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</p></td><td style="width: 20%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><img src="hdr.jpg" alt="">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-weight: bold; text-align: left">CONTACT</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify"><b>GENFIT</b> | Investors</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify">Tel: +1 (617) 714 5252 | <u>investors@genfit.com</u></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><b>PRESS RELATIONS</b> | Media</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">Bruno ARABIAN &ndash; Ulysse Communication | Tel : 06 87 88 47 26 | <u>barabian@ulysse-communication.com</u></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">Stephanie BOYER &ndash; GENFIT | Tel: +333 2016 4000 | <u>stephanie.boyer@genfit.com</u></p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 80%"><p style="font-size: 10pt; margin: 0pt 0 0pt 1pt; color: #706F61"><b>GENFIT</b> | 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos -
FRANCE | +333 2016 4000 | www.genfit.com</p>
</td>
  <td style="text-align: right; width: 20%">4</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>hdr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hdr.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #+ QL# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#I!X6\-_\
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MHV QYGX?UKF5^8WTL9O_  @WA'_H5=#_ /!?%_\ $TA\#>$?^A5T3_P7Q?\
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M;-/!I@8?_"#>$?\ H5M$_P#!?%_\31_P@WA'_H5M$_\ !?%_\36\*6D!@?\
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M.E)%,P?^$&\(_P#0K:)_X+XO_B:7_A!O"/\ T*NA_P#@OB_^)K>I<U1!@?\
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M07YS2)L/)XZU7E;@TK.QZ5"ZN><4F4D0%OFJW!VJB0P>KML>15193V-%(]Q
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M\,:O)/<R0>(/L4%LFZ.0/D2'M^-<[8^&SJQ9;:\M9F8[@COM;)_K3Y!JOAB
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M3L4N4=R'RA3@F*DI#3L(C:F5(U-Q0P%%2J:BQ4@K-EHE%/J,&G4P%IIIU--
M$;"H\5,U1XJD2P IXIN*>!3$+2YHHH *JZ@N;"X'JAJU4%Y_QYS?[AH X&:W
M;)XK,NK,GI742H#5)X0V>*J4M"8JS.3$3Q38R<5KVWW0*EFL\MG%+'%L(XKA
MJ,[J:N7(5]:U[7'%9<=7[=L8YJ*<]32<=#9A(J_$V!63"_O6A"P]:[8NZ.&2
MU+ZGBG5$AXJ4=*LDC?I7R)\9_P#DK.M_]L/_ $1'7UZV,5\A_&C_ )*UKG_;
M#_T1'0]@/5;.S#2 XK>@ML#  Q5&QP' K<A4<5YU-7/1J.P1P"IOLP(Z5-&O
M-652NA1.>4S--HJG(6HGA'IUK4D2JSJ1D]<5HE9F,]3E_$J>7X9U)AVB-?/M
MM(J7@+#.>@KZ.\3Q;_#6IJ.\1-?-L6T72[N!R"?2M;F:5BZ)U^R30+ @8L3N
M(^;\*:LMI);*B6R!U'^L'#$U*;>":XV?:##&%^4]2351X+B20K JL8_O<]??
MZT -6U;:+E9U+$D%#UJ**(H[M(H#=12C>F]G##V;M2L^^W\WKNZT 5I)"S\'
MOVJP&\NWSGD^M'DV[QY4D-4LMC(UL)(Y$?'52>: N00W0 VN%.>Q&:U((=(N
MX&CE9[.?M)U4_A6;9VZEC)(=N.QJM++NE)4XYXQWI#1=GTB2TNHP\J2QD\2(
MW!%-U%X3.J0C:BCDCUIMM(PC9W/2EBN(7)61 0:!D=M-*TFP.VP=>:F>ZA>3
M9)&&0<5=@TVSN(6-K<>7<=HGZ'\:R+JTN;64I/$5)/![?G0!JVFE6-[(/+O1
M;N1\JR#()]/:J&I6=U9S[+B,JB\!E.5/XU)):FTL8IS(-[G.WTI\6KR^4()0
M)5/16YQ0!%:V-Q)9RWJ$+''R<GK5F#6RT7D7*^;'CHXS3R%DM_LOFK%N.=IZ
M54DTB\0^8L/F1C@LAR!0@+UF8X_-DMCY0D.T!CTK+N;"Z@9B\3,"?O@9'YT7
M$F J*?N=?:K6GZO=VW"$D'JK#*D4=1D(D,%IM4C<?2I[/6+FW91D,H^\C %3
M5JY2RU7$D6+>X].QJ#3;=+:\D>YC60(IQCH:!%NY-CK"EHD2TFQ]Q/N-6=9Z
M<W]II!>?+'GYRO<53:8F1GC./F/X5?M+@Q0M)*Q)]#WH AO)$MM1F6T8^4K?
M+]*LVET9Y/,G/RKWQS5F&VT74U&9I+*X_O'YHS5;4+*;34\KB2-NDJ<@TAEY
M=(M]6W2VNHQK<_\ /&?@L?8U3N(9M,C\J9"LS=\Y%4;.*:>;9""VT9)]*T%U
M(36[6MTNY>F>X-,FY'875[%NFA,OEQC+.AZ5TNBO;:C)>M=+'*9K<J[ 8(/;
MGUK(LGEM-$O(8@9/M1QA1VIMA=+I/EI'M=V^\#R!]:0T=)ITC:DUMHME(!Y3
M 1DG\R:?=V)L-7O;,S)+LD.)$Z5/ID=A86POK* O>SDQKSZ^E9&GL_GSK)NW
M!R&#>M"W!EL18%(8JER>XYH+>U400&.F%*G)]JC)YZ4QD)4TABS4Q;VIFX>E
M $)A'K3&B JPS#TJ/=FC4&7+ ^4RUU-G>[5'-<C"V"*T8KG:O6M(LSDKG6?;
MQMZUV?@6Y\Y;[GIY?_LU>2->D+PU>A?#"Y\U=3!.<>5_[/3D]!16IZ4#4JU7
M1LU.O2L34<:B:I*8PH K.#3$&#5AA30M "AJ:7-/VTPK0!/$V4J45!#]VIQF
MDQCJ8_2GTUONF@" U$6YJ0TP+DTQ#*55R:G6(4\1BD,8JU(!2[,4H%,08I<4
MM%(8VD(IX%."TQ$!4TW::M;::5I#*]/%/*4;<5+128E/!IM%*P[C\TAI,T4Q
M"&F&G&HZI"8\4\5&#3\TR1U)FDHI##-0W?-G-_N&K %1W 'V:3/]TTKCL<K(
MIQ4(0D]*U'C7'2H?*YJ)2NA\I1: &HC;#M6GY5)Y.>U<\U<Z(2LC**;:L02#
M.*FGA(7@51R8VKGDN5G3%\R-B&05HP.#6!#,#CFM:V?TKJI3N<]6!KQO4^[B
MJ<;5.&XKJ.05VXKY&^,IS\6-;_[8?^B(Z^M7:ODGXR?\E6UK_MA_Z(CIO8.I
M[!;3@3J:Z6V(=5(K@XKH!EY[UU6G7.Z-?FKSZ1Z-38Z*):MH .*SH)^.M74D
MS76CC8Z1>*K2+^M6F<5!(1C.>E,5C&U>(RZ3?)C[T+?RKYBE15NMCYQN()KZ
MJ=!()$/(="M?+^NVYM=7O(CD%)FP/3FK3(:"2WQ"D_F#<3A5'5:KGSTDW>68
MRPY![U-#%*5*PGS"1DFDEG>1=LI_> 8 )Z4R2&0I*J%V(4MAB.:9/!Y0:.%]
M\>>,]13Y+:(PY@=@&'S#L#44DAMXU!.6 YS0 V&/RE+-UJ(7$GF\=S5B;"Q1
MDG&\=:8UN%*LASCM0!)-)LC'8GK2)%:RK\P8?[0-5YS(QRR'&.U26D .9'R%
M'H:0S1FT666Q\S3YDN4ZL@X<?A67%;2-=>3(FQAP01R*='?2VTI>)BI!X8=:
MLB[:=VN)"0Q'7N:!W(;EA;W 2)C^[_G4T6I3SIY,A#+_ +7.*8EM%<\^>$E;
MKNJ232[O3XC--%F)ONR)\P- AS1P7C^4\WEL@P.XJ/\ LBZ@(D:+S(ASOCYK
M/+$'/KZ5J6U_=:>BY=E5N"O8BBPS/EE9Y2<@@<8JW9WMW;H9HV8(#C.>*EN7
ML+U?-""*;_9Z&EN%E_L]+>.(LHY.T4"L2SRV.IKYCA8[CNRCK26^+72KB-4$
MCN>"%S@5CH,R!#\I!Z=,5>.H2VLRB)L8'.>0:!F>-R.,$AB>E:<=T;.)&PI8
MG)!]*N6][IUZ=M]:*SG_ ):Q<$55U+3GC(EA?SH.S=Q0!<MQHVJO_I>ZSE/2
M6/D9]"*HZI9RVK"/(EB'W73H?K45G:;[2:XSCR^@-)%J<BQ^4_SJ.F>: N,L
M;9[AR0?E49)S5B#4WBW12?/'T"]JN6,0:)U21(3,.">U4[G1+VS<&6/,1/$R
M<J:8B[IJGS9)+; =E("G@5GM87,5R4N(V3)RS=J);@Q+Y<38 Y)[UIVFJ2^6
MJ71#1/Q\XJ0(HM4>UN%\G'EH,$X_I6O;1V=Q)=3/&JM/!SM['UK*AM8HVO.G
MED?)GFI-,F2V\NW(#!^&+=#0,Z;PS=0#=<RH6AT_$L: X)<=C5>SN!?ZE=7@
M7:)Y"^WTS4\1MO\ 28Q!MLX[<LP'&_TY[\U2T;]U'SV7BA+4'L:NWCUI-GM1
MYJTGFCUJR!I7VIA4>E.,BD]::77UH :4'I3-@]*D+KZTA8>M R%HP33#$*F)
M6DXH @V;3UJ=#D<FHS@TGT-.XK$QVXZUZ/\ ";#'5@.WD_\ L]>8-GUKT[X/
M+SJ_UA_]GH;T!+4]7BCXS5A5J->E3+4%!MI"M2 4$4 5F2H\8-6F'%0.,4Q,
M;32*=FD- "Q=2*G%5XC\]6!28QU--.S2&@"J?O4]%IC\/3T- $H'%.%-I10
MZFTM-)H 7-(.:;R34JK3$*HIX% %/ I#&XHQ3\48I 1[:0K4M)BF!%MII6IB
M*0B@"'%&#4N*,4 1;:394VVC% $.RFXQ4Y%1L* &9IP(J(T TFQI$^ZHKEL6
MLI]%-/%1W0_T27_=-9MZ%I:F"T^:=&=U02#':E@;FN=29U2@K%U8\TX)@]*D
MA&Y:E$=;)71A>Q3FBRIK!O4*&NGD3BL>_M\@D"LJD#6E/4RH)<-C-;=I*,5S
M+!XY"<'BKMI>%6P36,&XLWFDT=9')Q5E7R*R;64R <UJ1K[UVPE='#.-F.8Y
MKY,^,?\ R5;6O^V'_HB.OK797R7\91CXL:V/^N'_ *(CK2YF=FDA!!KI=*NO
MD4'K7S916,:5NIT.O?H?75M,"HJ^DAXKXVHK11,G,^S6D.*KO*:^.J*=A<Q]
M@K-^\4^]>!?$BR%IXPNQ_#)\_%>=T4UH)NYO61F1=ZL,#TJ;-N^X/&2YZ'/2
MN;HIW)L;DP:!0(L^NWVI&>&>53(/D88!]ZQ**+A8U9875=@.Y1TS3H1Y:;CS
M@5D447"QJ"Z)."F<U,_RQ^61C>:Q:*+C-86+/G8XW>AHN(I88E#Q,H(ZXXK)
MHHN*Q?CW[U5"-Q]:U(-4N--?RU=BK?>7J#^!KG**0S?G^R74Z301&-\Y8=C2
M:C]HNB)%BS'&,$BL&BG<#0MD!D)Z!>U6%U&:&X9XG*]JQZ*+@=9'>Z??QXNK
M4)/VGBX/XBLR^TV6WW2(XDB/1A6-12 VEMUATPS%OG8X %0Q7\R(4SE6X K+
MHIW$=/$+?[.()Y3&LG+.!TID_AVZBB%W%(ES9@\2(>1]17-T4AFI<2G<JKT0
M<5H66JW$%L0[,83P5)X_*N;HH W+V"%G$EN1\_4#I3KR(F.W@4XQU/I6#10!
MUEC*D+1V[ .K_>W4XP11PR>6"0LF]!7(T4 >@WETTF@6J*_63\0/2KNGVI>U
MW>K5YC133L#U1ZP;1L]::;1J\IHI\Q/*>IFT:FM;-ZUY=11S#L>G&V;UIIMW
M]:\SHHY@L>DF%Z/*>O-J*+A8]*$3D]*=Y+^E>9T4<P6/2FA:O3OA$I0:J#ZP
M_P#L]?,];6@>*];\,?:/['O?LWVC;YO[I'W;<X^\#C[QZ>M*X6/M9#D5,M?'
MG_"U_&W_ $&O_)6'_P"(H_X6OXV_Z#7_ )*P_P#Q%(9]CCI17QQ_PM?QM_T&
MO_)6'_XBC_A:_C;_ *#7_DK#_P#$4 ?8IJO+TKY"_P"%K^-O^@U_Y*P__$4?
M\+7\;?\ 0:_\E8?_ (B@#ZW!H)KY(_X6OXV_Z#7_ )*P_P#Q%'_"U_&W_0:_
M\E8?_B*=Q6/K>,X<5/NYKY!_X6OXV_Z#7_DK#_\ $4?\+7\;?]!K_P E8?\
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M_H-?^2L/_P 10!]DFHV%?'7_  M?QM_T&O\ R5A_^(H_X6OXV_Z#7_DK#_\
M$4 ?7KTQ>M?(O_"U_&W_ $&O_)6'_P"(H_X6OXV_Z#7_ )*P_P#Q%)JXT['V
M *9<G%K+_NFOD+_A:_C;_H-?^2L/_P 15>^^)/BW4K">RN]6\RWG0QR)]FB&
MY3U&0N1^%)Q&I:GU'*<BHX2-W%?&M%9*AYFSKW6Q]Q6P^6KBH,5\(T5JHV,6
M[L^[C'Q56>V##&*^&Z*'&XU*Q]F7&F98G%5TTOY\U\=T5G[%%^V9]M6EOY8
DK6C7@5\'T5<86,Y2N?>N*^1_C1Q\6M<_[8?^B(ZX*BK)/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
